Shots:

• The sBLA is based on data from the P- I/II ZUMA-3 trial in adult patients age ≥18 years old for the treatment of adult patients with r/r B-cell ALL
• The focus of the study is to evaluate the safety and efficacy in adult patients with r/r ALL
• If approved- Tecartus will be the 1st and only CAR T-cell therapy approved for adult patients. In July 2020- Tecartus received an accelerated approval from the US FDA for the treatment of r/r mantle cell lymphoma- based on ORR and DOR

  Ref: BusinessWire | Image: BusinessWire